News New Data on RTH258 Show Promise by Medscape • 2016/08/24 • 0 Comments A recent phase 1/2 trial shows that RTH258 is a promising alternative to ranibizumab for the treatment of neovascular age-related macular degeneration. Medscape Ophthalmology Full Story →